

Japanese Encephalitis (JE) Vaccine

Chip Walter, M.D.

Chair, ACIP Flavivirus Vaccines Workgroup

October 26, 2017

ACIP Flavivirus Vaccines Workgroup members

ACIP

Emmanuel Walter, ACIP

Robert Atmar

Cynthia Pellegrini

Ex Officio

Mark Challberg, NIH

Eric Deussing, DoD

Doran Fink, FDA

Mike Holbrook, NIH

Lewis Markoff, FDA

Jeff Roberts, FDA

ACIP liaisons

Elizabeth Barnett, AAP

Robert Schechter, AIM

CDC

Marc Fischer, DVBD

Mark Gershman, DGMQ

Susan Hills, DVBD

Mike McNeil, ISO

Erin Staples, DVBD

Steve Waterman, DVBD

Technical advisors

Edwin Asturias, Univ Colorado

Alan Barrett, Univ Texas Galveston

Joseph Bocchini, Louisiana State Univ

Lin Chen, Mount Auburn Hosp

Myron Levin, Univ Colorado

Tony Marfin, PATH

Hal Margolis, Consultant

Cody Meissner, Tufts Univ

Lorry Rubin, North Shore Univ Hosp

David Shlim, ISTM

Mary Wilson, Harvard Univ

ACIP JE Vaccine Workgroup objectives

- Review newly available safety and immunogenicity data for JE vaccine
- Review epidemiology and risk of JE in travelers
- Review ACIP recommendations for use of JE vaccine in consideration of updated safety, immunogenicity, and traveler risk data
- Update MMWR Recommendations and Reports published in 2010

Today's JE vaccine presentations

- Susan Hills (CDC/NCEZID)
 - JE among U.S. travelers
- Christian Taucher (Valneva Austria)
 - JE vaccine post-marketing adverse event surveillance among U.S. military personnel
- Susan Hills (CDC/NCEZID)
 - Adverse events following JE vaccine reported to VAERS, 2012-2016
 - ACIP JE Vaccine Workgroup summary and plans